Electronic letters to encourage cholesterol checks in people with ischemic heart disease
Tests electronic information letters in adults with ischemic heart disease and high LDL cholesterol.
Plain-language title generated from the registry record
Registry title: Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial
Key facts
- Where
- Hellerup, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Denmark with ischemic heart disease whose latest LDL cholesterol is above the target. Some will get an electronic information letter.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Ischemic heart disease first registered more than 6 months before the identification date and after January 1, 2000. Latest LDL cholesterol over 1.4 mmol/l (54 mg/dL), measured up to 3 years before the identification date.
- Biomarker or test result
- LDL cholesterol over 1.4 mmol/l (54 mg/dL). A subgroup also has elevated lipoprotein(a), 105 nmol/L or higher, or 50 mg/dL or higher.
Main reasons for not taking part
- Living in a nursing home
- Exempt from Digital Post, so no access to it
- Not alive or not living in Denmark on the identification date
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07382414, who can take part
Where in Denmark
- Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, 2900Hellerup, DenmarkContact: Tor Biering-Sørensen, MD, MSc, MPH, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tor Biering-Sørensen
- Trial code
- NCT07382414
- Record updated
- 8 September 2026
- Original description
The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL cholesterol above the recommended treatment target. A subgroup of participants with elevated lipoprotein(a) [Lp(a)] will also be randomized to receive an additional information letter.Read full original descriptionShow less
NUDGE-IHD: A Nationwide Pragmatic Randomized Trial of Electronic Nudges to Increase Patient Activation and Reduce Cardiovascular Events in Ischemic Heart Disease
The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL cholesterol above the recommended treatment target. A subgroup of participants with elevated lipoprotein(a) [Lp(a)] will also be randomized to receive an additional information letter.
The main questions the study aims to answer are:
* Does sending an electronic letter about elevated LDL cholesterol increase the proportion of patients who have at least one LDL-cholesterol test within 6 months? * Does sending an electronic letter about elevated LDL cholesterol reduce major adverse cardiovascular events (cardiovascular death, myocardial infarction, or stroke) over 5 years? * Among patients with ischemic heart disease and elevated Lp(a), does receiving an information letter about Lp(a) increase the proportion who have at least one LDL-cholesterol test within 6 months, and does it reduce major adverse cardiovascular events over 5 years?
Because this is a randomized trial, researchers will compare people who receive the electronic letter(s) with people who do not receive any letter to determine whether the letters encourage patients to take action, such as obtaining laboratory tests or contacting their doctor.
Participants will:
* Receive an electronic letter through Denmark's national digital mailbox system (Digital Post) or receive no letter, depending on random assignment. * Continue their usual health care, with no additional visits, treatments, or procedures required for the study. * Have all study information collected from existing Danish nationwide health registries.
Inclusion: Alive and resident in Denmark on the identification date; Diagnosis of IHD defined as an A (action) diagnosis code of I20-I25 in the Danish National Patient Register, first registered > 6 months prior to the identification date but after January 1, 2000; Latest available LDL-C is over 1.4 mmol/l measured up to 3 years prior to the identification date, defined using NPU codes NPU01568, NPU10171 or DNK35308 from the Danish National Laboratory Register; Age >= 18 years and <= 85 years on the identification date.
Exclusion: Exemption from, and thus no access to, Digital Post; Definition of the elevated Lp(a) subgroup (secondary study population) Participants in the primary study population who, in addition, have an elevated Lp(a) level recorded at any time prior to the identification date, identified in the Danish National Laboratory Register using NPU codes NPU21687 or NPU19840. Elevated Lp(a) is defined as >= 105 nmol/L or >= 50 mg/dL. Only participants in this subgroup undergo the second randomization to the Lp(a) letter; Nursing home residents.